In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin
- PMID: 8593023
- PMCID: PMC163033
- DOI: 10.1128/AAC.39.12.2798
In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin
Abstract
Adding rifampin to penicillin or l-ofloxacin diminished the rate at which these antibiotics killed 21 clinical isolates isolates of Streptococcus pneumoniae in vitro. A less pronounced inhibitory effect was observed when rifampin was added to ceftriaxone. Synergy was not observed for any bacterial isolate. The in vitro demonstration of indifference or antagonism using these antibiotic combinations argues against the empirical addition of rifampin to beta-lactams or fluoroquinolones in treating serious pneumococcal infections.
Comment in
-
Lack of correlation between in vitro and in vivo studies of combinations of rifampin plus vancomycin or beta-lactam antibiotics against Streptococcus pneumoniae.Antimicrob Agents Chemother. 1996 Jun;40(6):1573-4. doi: 10.1128/AAC.40.6.1573. Antimicrob Agents Chemother. 1996. PMID: 8726045 Free PMC article. No abstract available.
Similar articles
-
In vitro activity of newer quinolones on Streptococcus pneumoniae isolated from outpatients.Acta Clin Belg. 1998 Aug;53(4):285-6. doi: 10.1080/17843286.1998.11754177. Acta Clin Belg. 1998. PMID: 9795451 No abstract available.
-
In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance.J Antimicrob Chemother. 1999 Jun;43 Suppl C:15-9. doi: 10.1093/jac/43.suppl_3.15. J Antimicrob Chemother. 1999. PMID: 10404332
-
Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.Diagn Microbiol Infect Dis. 2002 Jul;43(3):207-17. doi: 10.1016/s0732-8893(02)00391-7. Diagn Microbiol Infect Dis. 2002. PMID: 12106954
-
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.Diagn Microbiol Infect Dis. 2001 Mar;39(3):195-7. doi: 10.1016/s0732-8893(01)00209-7. Diagn Microbiol Infect Dis. 2001. PMID: 11337189
-
Synergy and antagonism of combinations with quinolones.Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):255-61. doi: 10.1007/BF01966998. Eur J Clin Microbiol Infect Dis. 1991. PMID: 1864285 Review.
Cited by
-
In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin.Antimicrob Agents Chemother. 1996 Dec;40(12):2802-4. doi: 10.1128/AAC.40.12.2802. Antimicrob Agents Chemother. 1996. PMID: 9124844 Free PMC article.
-
Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis.Eur J Clin Microbiol Infect Dis. 2009 Jul;28(7):807-11. doi: 10.1007/s10096-009-0711-y. Epub 2009 Feb 17. Eur J Clin Microbiol Infect Dis. 2009. PMID: 19221815
-
Infected abdominal aortic aneurysm due to penicillin-, ceftriaxone-, and cefotaxime-resistant Streptococcus pneumoniae.J Clin Microbiol. 1997 Apr;35(4):985-7. doi: 10.1128/jcm.35.4.985-987.1997. J Clin Microbiol. 1997. PMID: 9157169 Free PMC article.
-
Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.Antimicrob Agents Chemother. 1999 Oct;43(10):2372-5. doi: 10.1128/AAC.43.10.2372. Antimicrob Agents Chemother. 1999. PMID: 10508009 Free PMC article.
-
Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.Drugs. 1998 Sep;56(3):487-515. doi: 10.2165/00003495-199856030-00013. Drugs. 1998. PMID: 9777318 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical